Ocata Therapeutics Inc fka OCAT

[rocky301]

Agreement has made it to the Roslin Cell website. Nice paragraph by Paul De Sosa, CSO of Roslin Cell.
(single blastomere lines: potential for more stable properties once expanded, genetically uniform and robust)
http://www.roslincells.com/sitepix/downloads/Press%20Release_Roslin_ACT_Blastomere_21Jun11.pdf

Paul De Sousa (Chief Scientific Officer)

Dr. Paul De Sousa has trained as a developmental and reproductive biologist, with a specific interest in mechanisms controlling the creation of developmentally competent eggs and embryos and cell regeneration. In 1998 he joined the Roslin Institute in Scotland where he began applying his basic research interests to animal biotechnology. In 2002 his group began focusing on the derivation of new human embryonic stem cells in accordance with emerging regulatory standards for therapeutic use. In 2005 he joined the University of Edinburgh as a Senior Research Fellow establishing a laboratory focused on the use of human embryonic stem cells in regenerative medicine and underpinning egg and embryo biotechnology. In concert with this he co-founded Roslin Cells Ltd.